Stryker expands its Foot & Ankle portfolio with FDA-cleared InCompass, targeting streamlined total ankle replacement.

Alphatec shows sales growth but faces challenges with persistent losses, shareholder dilution, and rising debt.

Stryker (NYSE:SYK) recently received FDA clearance for its Incompass® Total Ankle System, a significant product innovation that highlights the company's commitment to advancing patient care. Over the ...

In a report released today, Travis Steed from Bank of America Securities maintained a Buy rating on Stryker (SYK – Research Report), with a price target of $450.00. The companys ...

The star of Monday’s deal is gusacitinib, a small-molecule drug that Formation is developing for chronic hand eczema. Sanofi ...

The MedTech segment accounts for around 36% of J&J’s total revenues. Sales in the MedTech segment rose 4.1% on an operational ...

Stryker (NYSE:SYK) announced today that it received FDA 510(k) clearance for its Incompass total ankle system.

Penumbra's AI-guided aspiration system and scalable platform uniquely position it as a leader in stroke and PE intervention.

There has been a shift in leadership for the Digital, Robotics and Enabling Technologies business at Stryker (NYSE: SYK) + ...

New York-based Formation Bio, an AI-native pharma company focused on accelerating drug development, revealed that its ...